Key facts
- LIGAND PHARMACEUTICALS INC filed SCHEDULE 13D for XOMA ROYALTY CORPORATION Common Stock, par value $0.0075 per share (XOMA).
- Disclosed ownership: 47%.
- Date of event: 27 Apr 2026.
LIGAND PHARMACEUTICALS INC - 27 Apr 2026 SCHEDULE 13D Report for XOMA ROYALTY CORPORATION Common Stock, par value $0.0075 per share (XOMA)
- Filing manager
- LIGAND PHARMACEUTICALS INC
- Reporting owner
- Ligand Pharmaceuticals Incorporated
- Symbol
- XOMA
- Shares outstanding
- 17,154,634 shares
- Disclosed shares
- 8,062,678 shares
- Ownership percentage
- 47%
- Form type
- SCHEDULE 13D
- Filing time
- 01 May 2026, 21:15:02 UTC
- Event date
- 27 Apr 2026
- SEC filing
- View on sec.gov
Reporting parties
Subject security
Ownership signal
SEC evidence
Key filing fact
LIGAND PHARMACEUTICALS INC disclosed 47% ownership in XOMA ROYALTY CORPORATION Common Stock, par value $0.0075 per share (XOMA) on 27 Apr 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 01 May 2026, 21:15.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | 47% | 8,062,678 | 0 | 8,062,678 | /s/ Andrew Reardon | Andrew Reardon, Chief Legal Officer and Secretary | 0000886163 |
CIK / CUSIP context first